Cargando…

Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal

Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelayo, Rafael, Bertisch, Suzanne M., Morin, Charles M., Winkelman, John W., Zee, Phyllis C., Krystal, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146758/
https://www.ncbi.nlm.nih.gov/pubmed/37109268
http://dx.doi.org/10.3390/jcm12082933
_version_ 1785034655124160512
author Pelayo, Rafael
Bertisch, Suzanne M.
Morin, Charles M.
Winkelman, John W.
Zee, Phyllis C.
Krystal, Andrew D.
author_facet Pelayo, Rafael
Bertisch, Suzanne M.
Morin, Charles M.
Winkelman, John W.
Zee, Phyllis C.
Krystal, Andrew D.
author_sort Pelayo, Rafael
collection PubMed
description Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with the focus statement “Trazodone should never be used as a first-line medication for insomnia.” In addition, field surveys were sent to practicing physicians, psychiatrists, and sleep specialists to assess general support for this statement. Subsequently, a meeting with a seven-member panel of key opinion leaders was held to discuss published evidence in support and against the statement. This paper reports on the evidence review, the panel discussion, and the panel’s and healthcare professionals’ ratings of the statement’s acceptability. While the majority of field survey responders disagreed with the statement, the majority of panel members agreed with the statement based on the limited published evidence supporting trazodone as a first-line agent as they understood the term “first-line agent”.
format Online
Article
Text
id pubmed-10146758
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101467582023-04-29 Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal Pelayo, Rafael Bertisch, Suzanne M. Morin, Charles M. Winkelman, John W. Zee, Phyllis C. Krystal, Andrew D. J Clin Med Review Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with the focus statement “Trazodone should never be used as a first-line medication for insomnia.” In addition, field surveys were sent to practicing physicians, psychiatrists, and sleep specialists to assess general support for this statement. Subsequently, a meeting with a seven-member panel of key opinion leaders was held to discuss published evidence in support and against the statement. This paper reports on the evidence review, the panel discussion, and the panel’s and healthcare professionals’ ratings of the statement’s acceptability. While the majority of field survey responders disagreed with the statement, the majority of panel members agreed with the statement based on the limited published evidence supporting trazodone as a first-line agent as they understood the term “first-line agent”. MDPI 2023-04-18 /pmc/articles/PMC10146758/ /pubmed/37109268 http://dx.doi.org/10.3390/jcm12082933 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pelayo, Rafael
Bertisch, Suzanne M.
Morin, Charles M.
Winkelman, John W.
Zee, Phyllis C.
Krystal, Andrew D.
Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
title Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
title_full Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
title_fullStr Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
title_full_unstemmed Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
title_short Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
title_sort should trazodone be first-line therapy for insomnia? a clinical suitability appraisal
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146758/
https://www.ncbi.nlm.nih.gov/pubmed/37109268
http://dx.doi.org/10.3390/jcm12082933
work_keys_str_mv AT pelayorafael shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal
AT bertischsuzannem shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal
AT morincharlesm shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal
AT winkelmanjohnw shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal
AT zeephyllisc shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal
AT krystalandrewd shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal